Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | OGFRL1 | Q5TC84 | 13/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13543533 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2OGFRL1OPRL1TP53CYP11B2 | |
| SCHEMBL2635863 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2OGFRL1OPRL1TP53CYP11B2 | |
| SCHEMBL988877 | 0.82 | CCR5 (0.49) | SMN1; SMN2CYP11B2 | |
| SCHEMBL4022749 | 0.82 | CCR5 (0.49) | SMN1; SMN2CYP11B2 | |
| SCHEMBL4028493 | 0.82 | CCR5 (0.49) | SMN1; SMN2CYP11B2 | |
| SCHEMBL3529180 | 0.82 | NOS2 (0.44) | OGFRL1OPRL1TP53CYP11B2OPRM1 | |
| SCHEMBL13720260 | 0.82 | CCR5 (0.49) | SMN1; SMN2CYP11B2 | |
| SCHEMBL3863093 | 0.82 | CCR5 (0.49) | SMN1; SMN2CYP11B2 | |
| Hydrochloric Acid SCHEMBL1573806 | 0.81 | CCR5 (0.48) | SMN1; SMN2CYP11B2 | |
| Hydrochloric Acid SCHEMBL3525571 | 0.81 | CCR5 (0.48) | SMN1; SMN2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | SMN1; SMN2 4065/4885OGFRL1 210/4885OPRL1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.